Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions

SIMPLE SUMMARY: Tumor mutational burden (TMB) represents the number of mutations per megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined with next-generation sequencing. High values are an indicator of potential response to immunotherapy. With this systematic review...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawlor, Rita T., Mattiolo, Paola, Mafficini, Andrea, Hong, Seung-Mo, Piredda, Maria L., Taormina, Sergio V., Malleo, Giuseppe, Marchegiani, Giovanni, Pea, Antonio, Salvia, Roberto, Kryklyva, Valentyna, Shin, Jae Il, Brosens, Lodewijk A., Milella, Michele, Scarpa, Aldo, Luchini, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269341/
https://www.ncbi.nlm.nih.gov/pubmed/34206554
http://dx.doi.org/10.3390/cancers13133119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269341/
https://www.ncbi.nlm.nih.gov/pubmed/34206554
http://dx.doi.org/10.3390/cancers13133119

Ejemplares similares